Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149979 | 0.81 | MAPT (1.00) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL151103 | 0.79 | MAPT (0.95) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL9206204 | 0.79 | MAPT (0.95) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL151720 | 0.79 | MAPT (0.95) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL7224479 | 0.79 | MAPT (0.95) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL146416 | 0.79 | MAPT (0.86) | MAPTPOLBGAATSHRALDH1A1 | |
| SCHEMBL3107944 | 0.79 | NLRP3 (0.46) | MAPTTSHRALDH1A1 | |
| SCHEMBL7228795 | 0.77 | MAPT (0.91) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL9322332 | 0.77 | MAPT (0.91) | MAPTPOLBALDH1A1PKMHRH3 | |
| SCHEMBL6738785 | 0.77 | MAPT (0.91) | MAPTPOLBALDH1A1PKMHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707475-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | ARTEREZ, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707475-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | ARTEREZ, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707475-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | ARTEREZ, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220390454-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220288110-A1 | DRUG TREATMENT AND BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20200237798-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | ARTEREZ LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-10449209-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | ARTEREZ, LLC (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180036285-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | KARDIATONOS, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9867842-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | KARDIATONOS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170080006-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | KARDIATONOS, INC. (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080006-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | MPO, VCAM1, NOX4 | MAPT 1723/4885POLB 3588/4885GAA 1521/4885 |
| US-20200237798-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | PCSK9, LDLR, PCSK6 | MAPT 1439/4885POLB 3423/4885GAA 1111/4885 |
| US-20220288110-A1 | DRUG TREATMENT AND BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | AGER, LGALS2, LGALS8 | MAPT 1009/4885POLB 3345/4885GAA 392/4885 |
| US-10449209-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | PCSK9, LDLR, PCSK6 | MAPT 1439/4885POLB 3423/4885GAA 1111/4885 |
| US-20220390454-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | SDCBP, LGALS2, SDC1 | MAPT 1840/4885POLB 3010/4885GAA 438/4885 |
| US-11707475-B2 | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage | PCSK9, LDLR, PCSK6 | MAPT 1439/4885POLB 3423/4885GAA 1111/4885 |
| US-20180036285-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | PCSK9, LDLR, PCSK6 | MAPT 1439/4885POLB 3423/4885GAA 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.